{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Selective_Estrogen_Receptor_Degrader_AZD9496",
  "nciThesaurus": {
    "casRegistry": "",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally available selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon administration, SERD AZD9496 binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.",
    "fdaUniiCode": "DA9P7LN909",
    "identifier": "C122834",
    "preferredName": "Selective Estrogen Receptor Degrader AZD9496",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2116"
    ],
    "synonyms": [
      "(E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid",
      "AZD 9496",
      "AZD-9496",
      "AZD9496",
      "SERD AZD9496",
      "Selective Estrogen Receptor Degrader AZD9496"
    ]
  }
}